株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

人工呼吸器関連肺炎(VAP): パイプライン分析

Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 264097
出版日 ページ情報 英文 113 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
人工呼吸器関連肺炎(VAP): パイプライン分析 Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2016
出版日: 2016年07月27日 ページ情報: 英文 113 Pages
概要

人工呼吸器関連肺炎(VAP)は、気管チューブまたは気管開口による人工呼吸器装着後48時間以降に発症する肺炎で、下気道や肺質への微生物侵入が原因です。最も重要な兆候は熱、低体温、膿性痰、低酸素血です。

当レポートでは、人工呼吸器関連肺炎(VAP)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

人工呼吸器関連肺炎(VAP)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Achaogen Inc.
  • Adenium Biotech ApS
  • Aridis Pharmaceuticals LLC
  • AstraZeneca Plc
  • Cardeas Pharma Corp.
  • MedImmune, LLC
  • Meiji Seikaファルマ
  • Merck & Co., Inc.
  • Motif Bio Plc
  • Nabriva Therapeutics AG
  • Savara Inc.
  • Tetraphase Pharmaceuticals Inc.

治療薬の評価

  • 単独療法の製品
  • 併用療法の製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • (アミカシン + ホスホマイシン)
  • (アビバクタム + セフタジジム)
  • (セフトロザン硫酸塩 + タゾバクタムナトリウム)
  • (シラスタチンナトリウム + イミペネム + レレバクタム)
  • (シュードモナス菌 + 人工呼吸器関連肺炎) ワクチン
  • AA-139
  • Aerucin
  • アルベカシン
  • eravacycline
  • ホスホマイシン・トロメタミン
  • iclaprim mesylate
  • lefamulin acetate
  • MEDI-4893
  • Nu-2
  • Panaecin
  • panobacumab
  • plazomicin sulfate
  • Qn-2251
  • tedizolid phosphate
  • tosatoxumab
  • バンコマイシン塩酸塩

パイプライン製品の最新動向

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 注目情報とプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8304IDB

Summary

Global Markets Direct's, 'Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2016', provides an overview of the Ventilator Associated Pneumonia (VAP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP)
  • The report reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Ventilator Associated Pneumonia (VAP) therapeutics and enlists all their major and minor projects
  • The report assesses Ventilator Associated Pneumonia (VAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ventilator Associated Pneumonia (VAP)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ventilator Associated Pneumonia (VAP) Overview
  • Therapeutics Development
    • Pipeline Products for Ventilator Associated Pneumonia (VAP) - Overview
    • Pipeline Products for Ventilator Associated Pneumonia (VAP) - Comparative Analysis
  • Ventilator Associated Pneumonia (VAP) - Therapeutics under Development by Companies
  • Ventilator Associated Pneumonia (VAP) - Therapeutics under Investigation by Universities/Institutes
  • Ventilator Associated Pneumonia (VAP) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Ventilator Associated Pneumonia (VAP) - Products under Development by Companies
  • Ventilator Associated Pneumonia (VAP) - Products under Investigation by Universities/Institutes
  • Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development
    • Achaogen Inc.
    • Adenium Biotech ApS
    • Aridis Pharmaceuticals LLC
    • AstraZeneca Plc
    • Bayer AG
    • Cardeas Pharma Corp.
    • MedImmune, LLC
    • Meiji Seika Pharma Co., Ltd.
    • Merck & Co., Inc.
    • Motif Bio Plc
    • Nabriva Therapeutics AG
    • Savara Inc.
    • Shionogi & Co., Ltd.
    • Tetraphase Pharmaceuticals Inc.
    • Zavante Therapeutics, Inc.
  • Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (amikacin sulfate + fosfomycin) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (avibactam + ceftazidime) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (ceftolozane sulfate + tazobactam sodium) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (cilastatin sodium + imipenem + relebactam) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (Pseudomonas + ventilator associated pneumonia) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AA-139 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Aerucin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amikacin sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • arbekacin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eravacycline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fosfomycin tromethamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • iclaprim mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lefamulin acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MEDI-4893 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Nu-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PAC-I - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Panaecin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • panobacumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • plazomicin sulfate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Qn-2251 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-649266 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tedizolid phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tosatoxumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vancomycin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Ventilator Associated Pneumonia (VAP) - Dormant Projects
  • Ventilator Associated Pneumonia (VAP) - Discontinued Products
  • Ventilator Associated Pneumonia (VAP) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 28, 2016: New antibiotic Zavicefta approved in the European Union for patients with serious bacterial infections
      • Feb 24, 2016: Aridis Pharmaceuticals Expands Patent Portfolio for Several Fully Human Monoclonal Antibodies Against Infectious Disease Targets
      • Jan 07, 2016: Aridis Pharmaceuticals Reports Positive Phase 1 Clinical Results for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia
      • Dec 15, 2015: Iclaprim Clinical Trial Supplies Manufactured
      • Jun 30, 2015: Aridis Pharmaceuticals Receives FDA Fast Track Designation for Aerucin for Treating Hospital-Acquired and Ventilator-Associated Pneumonia
      • May 07, 2013: Cubist's Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ventilator Associated Pneumonia (VAP), H2 2016
  • Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Achaogen Inc., H2 2016
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Adenium Biotech ApS, H2 2016
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals LLC, H2 2016
  • Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca Plc, H2 2016
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Bayer AG, H2 2016
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Cardeas Pharma Corp., H2 2016
  • Ventilator Associated Pneumonia (VAP) - Pipeline by MedImmune, LLC, H2 2016
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2016
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Merck & Co., Inc., H2 2016
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Motif Bio Plc, H2 2016
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics AG, H2 2016
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Savara Inc., H2 2016
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016
  • Ventilator Associated Pneumonia (VAP) - Pipeline by Zavante Therapeutics, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Ventilator Associated Pneumonia (VAP) - Dormant Projects, H2 2016
  • Ventilator Associated Pneumonia (VAP) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Ventilator Associated Pneumonia (VAP), H2 2016
  • Number of Products under Development for Ventilator Associated Pneumonia (VAP) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top